Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,105 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: calcium Clear all
Recruiting Phase 2 Interventional

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"

NCT01677195
View directory record Official record
Conditions
Dietary Carcinogenesis
Interventions
ACCS100, Placebo
Drug
Lead sponsor
Texas Enterosorbents Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

NCT01665677
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Mehdi Hamadani
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Morgantown, West Virginia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

NCT00008294
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

NCT00616694
View directory record Official record
Conditions
Osteoporosis
Interventions
Actonel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 85 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

NCT00650637
View directory record Official record
Conditions
Diarrhea
Interventions
Calcium Carbonate, nelfinavir, lamivudine, loperamide, Calcium carbonate not administered, lamivudine + zidovudine
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Not applicable Interventional

The Effect of Severe Weight Loss and Protein Intake on Bone

NCT00472680
View directory record Official record
Conditions
Weight Loss
Interventions
Caloric restriction, high protein, Caloric restriction; normal protein, Nutrition Education
Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy

NCT02539342
View directory record Official record
Conditions
Oral Mucositis
Interventions
Caphosol, Biotene
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
View directory record Official record
Conditions
Healthy
Interventions
Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Early Phase 1 Interventional

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

NCT01881971
View directory record Official record
Conditions
HIV Seropositivity
Interventions
Placebo, Rouvastatin calcium
Drug
Lead sponsor
Alison Morris
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 5:48 PM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 5:48 PM EDT
Not yet recruiting Not applicable Interventional

REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

NCT07853716
View directory record Official record
Conditions
CAD - Coronary Artery Disease
Interventions
Heartflow Analysis
Device
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
40 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

NCT03958409
View directory record Official record
Conditions
Skeletal Anomalies, Kidney Transplant; Complications
Interventions
measurements to evaluate metabolic bone disease, standard care
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Early Phase 1 Interventional

Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving

NCT05305404
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Dexamethasone Oral, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

NCT05027048
View directory record Official record
Conditions
Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
Interventions
Calcium chloride, Saline placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pacifica, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

NCT00524186
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01005914
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

NCT00679367
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, lenalidomide, melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 30, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

NCT02906332
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pembrolizumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 30, 2026, 5:48 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

NCT00023998
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 30, 2026, 5:48 PM EDT
Not listed No phase listed Observational

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

NCT03053999
View directory record Official record
Conditions
Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
Interventions
Genome Sequencing, Data Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00873275
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
Biological · Drug · Genetic + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 30, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Alveolar Ridge Preservation With Putty Allograft vs. Putty Alloplast Graft

NCT05484492
View directory record Official record
Conditions
Alveolar Bone Resorption
Interventions
demineralized and mineralized combination putty bone allograft, calcium phosphosilicate putty alloplast graft
Biological
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 5:48 PM EDT